Court of Appeals for the Seventh Circuit May 27, 2003, 01-1952 (In Re Abbott Laboratories Derivative Shareholders Litigation)

Also known as

United States · · · 27-05-2003

HARLINGTON WOOD, JR., Circuit Judge.

This shareholder derivative suit arises from a consent decree between Abbott Laboratories (“Abbott”) and the Food and Drug Administration (“FDA”). The action was brought in federal court on behalf of Abbott shareholders against Abbott’s board of directors alleging that the directors breached their fiduciary duties and are liable under Illinois law for harm resulting from a consent decree which required Abbott to pay a $100 million civil fine to the FDA, withdraw 125 types of medical diagnostic test kits from the United States market, destroy certain inventory, and make a number of corrective changes in its manufacturing procedures after six years of federal violations. The district court dismissed the original complaint for failure to plead demand futility with particularity under Fed.R.Civ.P. 23.1 and has now dismissed the amended com

*799

plaint for the same reason. We reverse and remand for further proceedings.

I. BACKGROUND

Abbott, an Illinois corporation, is a diversified health care company that develops and markets pharmaceutical, diagnostic, nutritional, and hospital products. Abbott’s Diagnostics Division (“ADD”) manufactures hundreds of different kinds of diagnostic kits and devices, including tests which indicate the safety of donated blood, detect heart attacks, and identify cancerous tumors. These products are heavily regulated by the FDA and must be manufactured in accordance with the “Quality System Regulations” (“QSR”), 21 C.F.R. § 820, and the requirements of the “Current Good Manufacturing Practice” (“CGMP”), as defined in 21 C.F.R. § 820.1. These regulations expressly assign corporate management the responsibility to assure compliance with the CGMP. 21 C.F.R. § 820.20. The FDA periodically inspects manufacturing plants to ensure compliance.

During a six-year period from 1993 until 1999, the FDA conducted thirteen separate inspections of Abbott’s Abbott Park and North Chicago facilities.

Read the full text

This document is published by courtlistener.com.

Moonlit adds the citation network, article-level links and cross-references, which are available to search for free.